Georgia Tech researchers aim to improve trials outcomes, boost Rx compliance with sensor necklace

Share this article:
MedTrace sensor necklace
MedTrace sensor necklace

Researchers from the Georgia Institute of Technology (GIT) have devised an innovative medication monitoring device that could prove to be a useful tool for pharma researchers and marketers of the future.

Maysam Ghovanloo, assistant professor in GIT's School of Electrical and Computer Engineering, and graduate student Xueliang Huo, are the minds behind MagneTrace, a magnetic sensor necklace that can detect when specially designed medication passes through a patient's esophagus.

The date and time the patient swallows a special, magnetically enhanced, pill can be recorded on a handheld wireless device, such as a smartphone, carried on the user's body. That information can then be sent to the patient's doctor, caregiver or a family member over the Internet.

The GIT researchers hope their invention can aid other researchers and pharmaceutical companies conduct more accurate clinical trials of new drugs – trials where compliance is frequently determined by medication diaries kept by the patients.

“If each drug trial volunteer had to wear a MagneTrace necklace, the exact date, time and dose would be recorded, rather than relying on the patient's memory and honesty,” Ghovanloo said in a statement.

MedTrace can also be used to keep patients compliant with their prescribed medicines, defraying rising healthcare costs, the GIT researchers said.

“Forgetfulness is a huge problem, especially among the elderly, but so is taking the medication at the wrong time, stopping too early or taking the wrong dose,” Ghovanloo added. “Studies show that drug non-compliance costs the country billions of dollars each year as a result of re-hospitalization, complications, disease progression and even death.”

Further details on the device were published in the December 2007 issue of the IEEE Sensors Journal.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.